Products for Research Use Only
RegisterLogin

Niclosamide (GMP)

CAT: 0804-HY-B0497GSize: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0497GSize:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Niclosamide (GMP) is Niclosamide produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Niclosamide (BAY2353) is an orally active antihelminthic agent used in parasitic infection research[1]. Niclosamide is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells[4]. Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells[2][3][5].
CAS Number
50-65-7
Product Name Alternative
BAY2353 (GMP)
UNSPSC
12352005
Hazard Statement
H400-H410
Target
Antibiotic; Parasite; STAT
Type
GMP Small Molecules
Related Pathways
Anti-infection; JAK/STAT Signaling; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/niclosamide-gmp.html
Solubility
10 mM in DMSO
Smiles
O=C(NC1=CC=C([N+]([O-])=O)C=C1Cl)C2=CC(Cl)=CC=C2O
Molecular Formula
C13H8Cl2N2O4
Molecular Weight
327.12
Precautions
P273-P391-P501
References & Citations
[1]P Andrews, et al. The biology and toxicology of molluscicides, Bayluscide. Pharmacol Ther. 1982;19 (2) :245-95.|[2]Wei Chen, et al. Niclosamide: Beyond an antihelminthic drug. Cell Signal. 2018 Jan;41:89-96.|[3]Kei Satoh, et al. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma. Clin Cancer Res. 2016 Jul 15;22 (14) :3458-66.|[4]Xiaomei Ren, et al. Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. ACS Med Chem Lett. 2010 Sep 7;1 (9) :454-9.|[5]Chang-Jer Wu, et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother. 2004 Jul;48 (7) :2693-6.|[6]Xu M, Lee EM, Wen Z, et al. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nat Med. 2016;22 (10) :1101-1107.|[7]Jiao Y, Chen C, Hu X, et al. Niclosamide and its derivative DK-520 inhibit RANKL-induced osteoclastogenesis. FEBS Open Bio. 2020;10 (8) :1685-1697. doi:10.1002/2211-5463.12921
Shipping Conditions
Room temperature
Scientific Category
GMP Small Molecules
Clinical Information
No Development Reported

Related Products

CatalogName
HY-B0497-01Niclosamide
HY-B0497S2Niclosamide-d3
HY-B0497C-01Niclosamide (olamine)
HY-B0497ANiclosamide (sodium)
HY-B0497S1-01Niclosamide-13C6
HY-B0497BNiclosamide (monohydrate)
HY-B0497R-01Niclosamide (Standard)
HY-B0497CR-01Niclosamide (olamine) (Standard)
HY-B0497BSNiclosamide-13C6 (monohydrate)
HY-10219G-01Rapamycin (GMP)

Alternative Products

CatalogName
T0711-01Niclosamide

Popular Products